MK-677 (Ibutamoren): A Lot of Human Data, Little to Show for It

MK-677, also called ibutamoren, is one of the odder entries you’ll find in any peptide reference — because it isn’t actually a peptide. It’s a man-made molecule that tricks the body into releasing more of its own growth hormone. And unlike most of the products sold to the fitness and “anti-aging” crowd, it has been tested in real, randomized human trials (studies where people are randomly assigned to the drug or a dummy pill), including a two-year study and a 563-patient Alzheimer’s trial. That’s far more evidence than most of the compounds it sits beside can claim. Here’s the catch, though: MK-677 reliably moves the lab numbers everyone likes to point at, but no trial has ever shown it delivers a real-world benefit for any of the things it’s sold for.

What it is

MK-677 switches on the same receptor (a docking site on cells) that the natural hunger hormone ghrelin uses — the growth-hormone-secretagogue receptor, or GHSR-1a. It’s worth saying plainly to a peptide audience: MK-677 is not a peptide. It’s a small synthetic organic molecule (chemical formula C27H36N4O5S, weighing about 528.7 g/mol). That chemistry is exactly why you can swallow it as a pill and why it stays active in the body for a long time. True GH-releasing peptides like ipamorelin or GHRP-6, by contrast, have to be injected and clear out quickly.

It works in a roundabout way. By latching onto GHSR-1a in the pituitary and hypothalamus (the brain’s hormone-control centers), MK-677 boosts the body’s own natural, on-and-off release of growth hormone (GH), which then nudges up insulin-like growth factor-1 (IGF-1), a downstream signal GH produces. A single pill raises GH and keeps IGF-1 elevated for about 24 hours, which is why once-a-day dosing works. Because it leans on the body’s natural rhythm instead of injecting GH straight in, the GH rise stays closer to normal. But “closer to normal” doesn’t mean “side-effect free”: it raises cortisol (a stress hormone) in several studies — usually only briefly — and it ramps up appetite, which is exactly what you’d expect from something that mimics the hunger hormone.

One bit of marketing confusion is worth clearing up: MK-677 is often sold as a “SARM.” It isn’t one. SARMs act on the androgen (testosterone) receptor, while MK-677 acts on the ghrelin receptor. The label is simply wrong.

The claims

In legitimate research, MK-677 has been studied by Merck (1990s–2000s) and now by Lumos Pharma (2010s–2020s) for growth hormone deficiency in children and adults, frailty and muscle loss in older people, recovery after hip fracture, wasting conditions, obesity, and Alzheimer’s disease (the idea being that raising IGF-1 might help clear amyloid-beta, the protein that builds up in Alzheimer’s).

On the gray market, it’s pitched very differently — as a muscle-builder, fat-loss aid, recovery and sleep enhancer, bone-strength booster, and anti-aging compound. Almost all of those claims rest on the IGF-1 rise — a stand-in marker — rather than on any trial that actually measured whether people got stronger, leaner, or healthier.

The evidence

This is where MK-677 stands apart: the human data really do exist. The trouble is what they show.

A two-year randomized, double-blind, placebo-controlled trial (the gold standard, where neither the patients nor the doctors know who’s getting the drug) in 65 healthy adults aged 60–81 (Nass et al., Annals of Internal Medicine, 2008) is the best long-term study we have. MK-677 pushed GH and IGF-1 up into the young-adult range and kept them there for two full years, with no fading of the effect over time. Fat-free mass (muscle and other lean tissue, not fat) went up about 1.1 kg, versus a 0.5 kg loss on placebo. But here’s the key part: that extra lean mass produced no improvement in strength or physical function. Meanwhile, fasting blood sugar rose and the body’s response to insulin got modestly worse. In short, the surrogate markers (the easy-to-measure stand-ins) improved, and the outcomes that actually matter did not.

A large Alzheimer’s trial (Sevigny et al., Neurology, 2008; funded by Merck) included 563 patients with mild-to-moderate disease. IGF-1 rose 60.1% at six weeks and 72.9% at twelve months — clear proof the drug was hitting its target — yet there was no effect on any measure of thinking or daily function. A clean, well-designed failure.

A hip-fracture recovery trial (Adunsky et al., Archives of Gerontology and Geriatrics, 2011) enrolled 123 elderly patients. Their physical recovery didn’t improve in any meaningful way, and the trial was stopped early over a heart-safety concern: 4 cases of congestive heart failure (the heart struggling to pump well enough) on MK-677 versus 1 on placebo.

Smaller, shorter studies help fill in how it works. An 8-week trial in 24 obese men (Svensson et al., JCEM, 1998) raised GH, IGF-1, and fat-free mass, with a brief bump in metabolic rate but no real change in total or belly fat. A small sleep study (Copinschi et al., 1997) found more slow-wave (deep) and REM sleep. A bone study (Murphy et al., 1999) raised markers of bone turnover — again a stand-in, not actual fracture-rate data.

The one live thread today is LUM-201 for children with growth hormone deficiency. Lumos Pharma’s Phase 2 trials (OraGrowtH210/212) reported that kids grew about 8 cm/year at one year, compared with about 9.7 cm/year on injected lab-made human GH, and the company says it plans to run a Phase 3 trial. But these are company-reported, open-label results (everyone knew who got what) in children with a diagnosed deficiency — not the healthy adults the gray market sells to, and not yet confirmed by the larger, stricter trials needed for approval.

The animal research was extensive and looked promising, including a 2018 study in a mouse model of Alzheimer’s that reported less amyloid buildup — a hopeful idea the human Neurology trial then failed to confirm. It’s a textbook example of animal promise that didn’t carry over to people.

What’s missing is the entire marketing pitch: no trial shows it builds usable muscle strength or function, drives healthy fat loss, speeds recovery, or slows aging in healthy adults — and there are no long-term safety trials in healthy people at all. The best long-term data we have (two years) is in the elderly, and it flagged worsening blood sugar. The major trials were also funded by Merck or other sponsors, which is normal but still calls for the usual caution — especially with the favorable, open-label pediatric results.

Safety and side effects

The most serious documented warning sign is about the heart and fluid: the hip-fracture trial was stopped early because of extra cases of congestive heart failure (4 versus 1). Swelling in the lower legs comes up consistently, and fluid retention with possible effects on blood pressure fits with how the drug works.

On metabolism, the two-year trial found rising fasting blood sugar and a weaker response to insulin — directly relevant for anyone who is diabetic or prediabetic. On the hormone side, MK-677 raises cortisol in several studies (often only briefly) and raises IGF-1 a lot, for long stretches. What that sustained IGF-1 elevation means over the long haul — including the theoretical worry, shared across the whole GH/IGF-1 system, that it could help feed cancer growth — isn’t established in healthy long-term users.

The more common, milder effects include increased appetite, water retention and swelling, muscle or joint aches, fatigue, and nausea. And because it’s sold outside regulated channels, real-world products carry an extra risk: they may contain too little, too much, or contaminants, with no quality checks at all.

This is informational only and not medical advice.

Legal and regulatory status

MK-677 has never been approved for any use, anywhere. It’s an investigational drug — still in testing. The FDA treats ibutamoren as something that can’t legally be a dietary supplement, so any product selling it as one is considered adulterated or mislabeled. The agency has sent warning letters to sellers, including Warrior Labz SARMS (June 12, 2023) and Agebox Inc. (December 19, 2025, over children’s growth supplements found to contain undeclared ibutamoren). The Department of Defense’s Operation Supplement Safety says it’s not approved for human use and not legal in dietary supplements, and notes it’s often sold deceptively under labels like “Supplement Facts,” “Research Facts,” or “For Research Use Only.”

In sport, WADA (the World Anti-Doping Agency) bans ibutamoren at all times under Section S2 (peptide hormones, growth factors, and mimetics), in the growth-hormone-secretagogue group, where it was added as a named example on the 2024 Prohibited List. It also shows up on the DoD Prohibited Dietary Supplement Ingredients List.

The gray-market reality: it’s widely sold online as capsules or liquid labeled “research chemical” or “SARM.” These are unapproved, unregulated products whose true identity, purity, and dose are unverified. “Research use only” is a legal shield for the seller, not a promise about quality or safety.

Bottom line

MK-677 is the rare gray-market compound that’s actually been put through serious human trials — and that’s precisely why its weaknesses show so clearly. It does what its biochemistry promises: it raises growth hormone and IGF-1, modestly bumps up lean mass, and may deepen sleep. But across two decades of randomized trials, those changes never turned into what people are really after — more strength, better function, healthy fat loss, sharper thinking, or healthier aging. One trial was stopped over a heart-failure signal, and the long-term data point to worsening blood sugar. It’s investigational, unapproved, banned in sport, and illegal in supplements. The honest grade is “Preliminary human,” and it lands at the cautionary end of that range: lots of data, consistent effects on the stand-in markers, and a discouraging record on the things that actually count.

Sources

• Patchett AA, et al. PNAS 1995;92(15):7001–7005
• Patchett 1995 — full text (PMC)
• Nass R, et al. Ann Intern Med. 2008;149(9):601–611
• Sevigny JJ, et al. Neurology. 2008;71(21):1702–1708
• Adunsky A, et al. Arch Gerontol Geriatr. 2011;53(2):183–189
• Svensson J, et al. J Clin Endocrinol Metab. 1998;83(2):362–369
• Copinschi G, et al. Neuroendocrinology. 1997;66(4):278–286
• Murphy MG, et al. J Bone Miner Res. 1999;14(7):1182–1188
• MK-0677 in 5XFAD Alzheimer’s mouse model (2018, PMC)
• Lumos Pharma — LUM-201 pipeline
• Healio — LUM-201 Phase 2 coverage (2024)
• FDA — Warning letter, Warrior Labz SARMS (06/12/2023)
• FDA — Warning letter, Agebox Inc. (12/19/2025)
• FDA — consumer alert, Agebox iKids Growth Day Formula
• DoD Operation Supplement Safety — MK-677 (Ibutamoren)
• WADA Prohibited List
• USADA — key changes to the 2024 Prohibited List
• Ibutamoren — Wikipedia